机构：[1]Department of Hematology, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China[2]School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong[3]Department of Pediatric Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China[4]Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, Guangdong, China
Neuroblastoma is an embryonal tumor of the sympathetic nervous system. The MYCN oncogene is amplified in some neuroblastoma patients and correlated with poor prognosis. However, less is known regarding the relationship between MYCN gene single-nucleotide polymorphisms (SNPs) and neuroblastoma risk.
To investigate the contribution of MYCN gene polymorphisms to neuroblastoma risk, we performed a 3-center case-control study by genotyping 4 SNPs in the MYCN gene from 429 cases and 884 controls.
The results showed that only rs57961569 G>A was associated with neuroblastoma risk (GA vs GG: adjusted odds ratio =0.76, 95% confidence interval =0.60-0.98, P=0.033), while the other 3 SNPs were not (rs9653226 T>C, rs13034994 A>G, and rs60226897 G>A). Stratified analysis revealed that rs57961569 GG carriers were more likely to develop neuroblastoma in the following subgroups: children older than 18 months, tumor derived from the adrenal gland, and clinical stages III + IV. The increased neuroblastoma risk associated with the rs9653226 variant CC genotypes was more evident in the following subgroups: females, tumor derived from the adrenal gland, and clinical stages III + IV. The presence of 2-3 risk genotypes had a significant relationship with the following subgroups: tumor derived from the adrenal gland and clinical stages III + IV.
This study demonstrates a weak impact of MYCN gene polymorphisms on neuroblastoma risk, which should be further validated.
基金：
This study was funded by grants from the Pearl River S&T
Nova Program of Guangzhou (No: 201710010086), the Scientific
Research Foundation of Wenzhou (No: 2015Y0492),
the Zhejiang Provincial Medical and Health Science and
Technology plan (No: 2009A148), and the Zhejiang Provincial
Science and Technology Animal Experimental Platform
Project (No: 016C37113).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|2 区医学
小类|3 区肿瘤学
最新[2025]版：
大类|4 区医学
小类|4 区肿瘤学
第一作者：
第一作者机构：[1]Department of Hematology, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Hematology, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China[4]Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, Guangdong, China[*1]Department of Hematology, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, 109 West Xueyuan Road, Wenzhou 325027, Zhejiang, China[*2]Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou 510623, Guangdong, China
推荐引用方式(GB/T 7714)：
Haixia Zhou,Zhenjian Zhuo,Shanshan Chen,et al.Polymorphisms in MYCN gene and neuroblastoma risk in Chinese children: a 3-center case-control study.[J].Cancer management and research.2018,10:1807-1816.doi:10.2147/CMAR.S168515.
APA：
Haixia Zhou,Zhenjian Zhuo,Shanshan Chen,Jie Zhao,Yixiao Mo...&Jichen Ruan.(2018).Polymorphisms in MYCN gene and neuroblastoma risk in Chinese children: a 3-center case-control study..Cancer management and research,10,
MLA：
Haixia Zhou,et al."Polymorphisms in MYCN gene and neuroblastoma risk in Chinese children: a 3-center case-control study.".Cancer management and research 10.(2018):1807-1816
：